Radiopharm Theranostics Limited

RADXNASDAQHealthcare● Active

$4.21

$-0.11(-2.55%)

Market Cap$5423322

P/E Ratio—

52W High$16.25

52W Low$3.62

Avg Volume157K

Open$4.35

Beta0.80

Forecast Market Cap PE Ratio

Radiopharm Theranostics Limited（RADX）股价预测与分析师目标价

华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。

radx · 股价预测 · 1 位分析师（近3月）· FMP · 更新于 2026年6月8日

分析师评级与共识

基于过去 3 个月内 1 位华尔街分析师

Buy

1 位分析师

共识

评级分布

Strong Buy

Buy

Hold

Sell

Strong Sell

合计: 1 · 买入占比: 100.0%

12 个月目标价

High

$15.00

Consensus

$10.50

+149.4% upside

Low

$6.00

Median: $10.5 · Last Close: $4.21

Radiopharm Theranostics Limited（RADX）的分析师共识为 Buy，基于过去 3 个月内 1 位华尔街分析师的评级。RADX 的 12 个月平均目标价为 $10.50，相对当前价 $4.21 代表 +149.4% 的潜在上行空间。

12 个月目标价预测

历史收盘价 + 分析师 12 个月目标价预测区间

Historical priceConsensus $11 (149.4%)High $15Low $6

Consensus Target

$10.50

149.4% upside

High Target

$15

256.3%

Low Target

42.5%

Current Price

$4.21

as of today

Based on analyst price targets, the RADX stock price prediction for the next 12 months ranges from $6 to $15. The consensus RADX price forecast of $10.50 implies 149.4% upside from the current price of $4.21.

短期股价预测

算法生成 · 每日更新

Date	Predicted Price	Change	Min	Max
2026-06-09	$4.16	↓ 1.10%	$4.14	$4.19

1-day model range: $4.14–$4.19. Peak: $4.19 (-1.10%).

长期股价预测

⚠️ 在满 252 个交易日历史（IPO/上市时间较短）前不展示长期预测；短期标签页仍可能显示模型输出。

基于技术分析的股价预测

14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明

Market Sentiment

BEARISH

Based on 14 technical indicators

7%14%79%

1Buy

2Neutral

11Sell

RSI (14)28.9Oversold

MACDBEARISH

Refreshes daily from EOD close

Moving Averages · RADX · Jun 9, 2026

Simple Moving Average (SMA)

MA 5$4.44SELL

MA 10$4.52SELL

MA 20$4.53SELL

MA 50$4.49SELL

MA 100$4.69SELL

MA 200$0.00NEUTRAL

Current $RADX · Price above MA = BUY signal

Exponential Moving Average (EMA)

EMA 5$4.40SELL

EMA 10$4.47SELL

EMA 20$4.50SELL

EMA 50$4.55SELL

EMA 100$4.74SELL

EMA 200$0.00NEUTRAL

Current $RADX · Price above MA = BUY signal

How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Date	Brokerage	Action	Rating
2025-12-16	B. Riley Securities	Maintains	Buy→Buy
2025-11-26	B. Riley Securities	Maintains	Buy→Buy

分析师推荐趋势

Buy ratings1 → 1

Hold ratings0 → 0

Sell ratings0 → 0

RADX analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.

财务预测：EPS 与营收一致预期

Revenue This Year

$3M

↓ 90.3% YoY

Revenue Next Year

$3M

↑ 10.1% YoY

EPS This Year

$-4.82

EPS Next Year

$-5.88

↑ 21.8% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast RADX EPS of $-4.82 for the current fiscal year, based on estimates from 2 analysts. The RADX revenue forecast is $3M for the current year. These are analyst consensus estimates via FMP / S&P Global.

关于预测与目标价

RADX 股价预测由两类独立数据源支撑：来自 1 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。RADX 的共识目标价为 $10.50（+149.4% 上行空间），分析师共识为 Buy。

RADX 的短期预测（明日）为 $4.16（-1.10%）。

Radiopharm Theranostics Limited 在 NASDAQ 上市，代码 RADX。RADX 在 2027 年的整体展望偏积极，在覆盖分析师中约 100% 对应 Buy 共识。

常见问题答案综合分析师目标价、一致预期及页面展示的模型结果。

常见问题

RADX 预测 · 8 个问题

根据 1 位华尔街分析师，RADX 的 12 个月平均目标价为 $10.50，最高 $15.00、最低 $6.00。若有图表，中位目标价可在上方查看。相对当前价 $4.21，隐含约 +149.4% 的上行空间。

RADX 目标价RADX 分析师目标价RADX 12个月目标价目标价 RADX

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.